Sudden death in athletes Rewiev

Öz

-

Anahtar Kelimeler

• -

Sporcularda ani ölüm Derleme

Öz

bir öykü, aile öyküsü ve fizik muayenenin yanısıra elektrokardiyografi ile değerlendirme birçok kalp hastalığının dışlanmasını sağlayacaktır

Anahtar Kelimeler

• ani ölüm, spor ölümleri, sporcu kalbi

Kaynakça

1. Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92.
2. Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
3. Cheitlin MD, Douglas PS, Parmley WW. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
4. Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
5. Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
6. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
7. Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
8. Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.

9. Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
10. Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
11. Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
12. Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
13. Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
14. Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
15. Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48.
16. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
17. Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
18. Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
19. Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
20. Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30.
21. Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804.
22. Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
23. Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
24. Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8. 1.
25. Luckstead EF. Cardiac risk factors and participation guidelines
26. for youth sports. Pediatr Clin N Am 2002; 49: 681-707. 2.
27. Germann CA, Perron AD. Sudden cardiac death in athletes:
28. Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92. 11. Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
29. Cheitlin MD, Douglas PS, Parmley WW. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
30. Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
31. Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
32. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
33. Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
34. Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.
35. Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
36. Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
37. Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
38. Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
39. Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
40. Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
41. Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
42. Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
43. Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
44. Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
45. Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30. Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804. Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
46. Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
47. Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8. 1.
48. Luckstead EF. Cardiac risk factors and participation guidelines
49. for youth sports. Pediatr Clin N Am 2002; 49: 681-707. 2.
50. Germann CA, Perron AD. Sudden cardiac death in athletes:
51. Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92.
52. Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
53. Cheitlin MD, Douglas PS, Parmley WW. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
54. Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
55. Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
56. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
57. Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
58. Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.
59. Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
60. Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
61. Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
62. Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
63. Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
64. Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
65. Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
66. Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
67. Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
68. Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
69. Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30. Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804. Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
70. Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
71. Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8. 1.
72. Luckstead EF. Cardiac risk factors and participation guidelines
73. for youth sports. Pediatr Clin N Am 2002; 49: 681-707. 2.
74. Germann CA, Perron AD. Sudden cardiac death in athletes:
75. Thompson PD. Klocke FJ, Levine BD, VanCoup SP. 26th Bethesda Conference: re commendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 5: coronary artery disease. JACC 1994; 24: 888-92.
76. Maron BJ, Isner JM, Mc Kenna WJ. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. JACC 1994; 24: 880-5.
77. Cheitli n MD, Douglas P S, Parmley WW. 26th Bethesd a Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 2: acquired valvular heart disease. JACC 1994; 24: 874-80.
78. Graham TP, Bricker JT, James FW, Strong WB. 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 1: Congenital heart disease. JACC 1994; 24: 867- 73.
79. Maron BJ, Zipes DP. 36th Bethesda Conference Introduction: Eligibility recommendations for competitive athletes with cardiovascular abnormalities- General considerations. JACC 2005; 45: 1318-21.
80. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109: 2807-16.
81. Cook S, Franklin WH. Evaluation of the athlete who ‘goes to ground’. Prog Pediatr Cardiol 2001; 13: 91-100.
82. Denfield SW, Gajarski RJ, Towbin JA. Cardiomyopathies. In: Garson A, Bricker JT, Fisher DJ, Neish SR (eds). The science and practice of pediatric cardiology. Second edition. Baltimore: Williams and Wilkins, 1998: 1851-84.
83. Ayabakan C, Akalın F, Mengütay S, Çotuk B, Odabaş I, Özüak A. Athletes heart in prepubertal male swimmers. Cardiology in the Young 2005; 16: 61-6.
84. Pate RR, Durstine JL. Exercise physiology and its role in clinical sports medicine. South Med J 2004; 97: 881-5.
85. Maron BJ. Distinguishing hypertrophic cardiomyopathy from athletes heart: a clinical problem of increasing magnitude and significance. Heart 2005; 91: 1380-2.
86. Pellicia A, Maron BJ, Di Paolo FM, et al. Prevelance and significance of left atrial remodeling in competetive athletes. JACC 2005; 46: 690-6.
87. Hart G. Exercise induced hypertrophy: a substrate for sudden death in athletes? Exp Physiol 2003; 88: 639- 44.
88. Elçioğlu NH, Akalın F, Elçioğlu M, Comeglio P, Child AH. Neonatal Marfan Syndrome caused by an exon 25 mutation of the fibrillin-1 gene. Genet Couns 2004; 15: 219-25.
89. Trusty JM, Beinborn DS, Jahangir A. Dysrythmias and the athlete. AACN Clinical Issues 2004; 15: 432- 48. Kyndt F, Probst V, Potet F, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation 2001; 104: 3081-6.
90. Francis J, Sakar V, Nair VK, Priori SG. Cathecolaminergic polymorphic ventricular tachycardia. Heart rhythm 2005; 2: 550-4.
91. Arias MA, Fernandez-Guerrero JC, Herrador J, Pagola C. Cathecolaminergic ventricular tachycardia as a cause of sudden death in athletes. Amj Emerg Med 2006; 24: 253-4.
92. Tanaka Y, Yoshinaga M, Anan R, et al. Usefuness and effectiveness of cardiovascular screening of young adolescents. Med Sci in Sports Exerc 2006; 38: 2-6.
93. Maron BJ. How should we screen competetive athletes for cardiovascular disease? Eur Heart J 2005; 26: 428-30. Wren C. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804. Corrado D, Pellicia A, Bjİrnstad HH, Thiene G. Cardiovascular pre-participation screening of young competitive athletes: proposal for a common European protocol. Eur Heart J 2005; 26: 1804-5.
94. Hulkower S, Fagan B, Watts J. Do preparticipation clinical exams reduce morbidity and mortality for athletes? J Fam Pract 2005; 54: 628-30.
95. Paterick TE, Paterick TJ, Fletcher GF, Maron BJ. Medical and legal issues in cardiovascular evaluation of competetive athletes. JAMA 2005; 294: 3011-8.